166 million! Maccura wholly owned acquisition of Dawei Bio

The semi-annual report shows that Maccura spent 166 million CNY to complete the acquisition of 100% equity of Beijing Dawei Biotechnology Co., Ltd. (hereinafter referred to as " Dawei "). In November 2020, Dawei opened the PRE-A round of financing. Maccura once subscribed for 3.4722% equity of Dawei with 5 million CNY. At the same time, the two sides launched strategic cooperation on the supporting development of digital PCR instruments and reagents.

It is reported that Dawei has established the international first chip free digital PCR instrument platform, and has original and independent intellectual property rights. This core technology realizes a new vibrating droplet generation method, which can quickly and efficiently complete the whole process of digital PCR without any chip structure, making the digital PCR technology truly feasible for clinical application.

On July 15, Maccura disclosed the first semi-annual report of Shenzhen stock market. In the first half of the year, the company achieved an operating revenue of 1.782 billion CNY, a year-on-year decrease of 9.11%; The net profit attributable to the parent company was 406 million CNY, a year-on-year decrease of 23.68%; The basic earnings per share is 0.6728 CNY. Among them, the sales revenue of independent products was 1.136 billion CNY, a year-on-year decrease of 1.84%, and the sales revenue of agency products was 626 million CNY, a year-on-year decrease of 20.17%.

In the report, Maccura pointed out that with the continuous improvement of the company's ability of independent products, and the cost advantage of independent products is much higher than that of agency products, the company has adjusted its business structure. In recent years, the company's independent products have maintained rapid growth, and their proportion in sales revenue has increased rapidly. During the reporting period, the proportion of independent product sales increased from 57.77% to 63.73%.

In terms of R & D, as of the end of the reporting period, the company had 853 R & D personnel, accounting for 29.77% of the total number of employees. There were 404 R & D personnel above middle and senior levels, including 49 senior and above core R & D teams. During the reporting period, the R & D investment was 123 million CNY, an increase of 10.94% over the same period last year. The company added 24 domestic product registration certificates, and by the end of the reporting period, it had obtained 440 domestic product registration certificates, including 128 biochemical products, 177 immune products, 82 clinical tests (including blood cells, coagulation, blood type, urine, pathology), 10 molecular products, 23 rapid tests, and 20 instrument products.

On February 25th, 2021, Dawei, an innovative microfluidic driven molecular diagnostic technology, announced that it had signed a strategic cooperation agreement with Maccura, a leading listed company in clinical in vitro diagnostics in China. The two sides will carry out in-depth cooperation on the new generation of molecular diagnosis technology, give full play to the high-throughput,  enclosed, automated and other characteristics of microfluidic technology.